List of available information in each column of AqSolDB. by Bin Pan (742525)

Subjects:

3D Scatter plot of features related to water-soluble materials. by Bin Pan (742525)

Subjects:

Workflow diagram of the prediction algorithm framework. by Bin Pan (742525)

Subjects:

The Ishihara test for colourblindness [41] encompasses stimuli that can determine the degree and type of colourblindness a person has. by Marcel F. Hinss (14675457)

Model A: Logistic structural model. by Abigail A. Lee (19935335)

“…Additionally, higher income slightly predicted decreased HPV vaccine hesitancy. All other latent variables and covariates were not significantly predictive of intent to vaccinate in the overall structural mode. …”

Movement variability conditioned on task outcome. by Adam M. Roth (19845864)

Validation of distinct contribution of capsule and hypercapsule-associated HMV in IFA-conferred protection against hvKP infection using a <i>ΔrmpD</i>-K7 mutant. by Tingting Wang (123983)

Results of two-way ANCOVA for <i>InR</i> and <i>Thor</i> expression differences by temperature and nutritional state interaction with <i>FoxO</i> as a covariate. by Tucker Hopkins (20790529)

(A) Serotonin and (B) Dopamine levels in brain tissues. by Hammad Ismail (4227988)

Table 1_Dual variants of uncertain significance in a case of hyper-IgM syndrome: implications for diagnosis and management.docx by Nourhen Agrebi (14151222)

“…</p>Methods<p>We present immunological and genetic analysis of a Tunisian patient with two homozygous variants of uncertain significance (VUSs) in the IKBKB and AICDA genes, suspected of causing hyper-IgM and immune deficiency. …”

Estimates of average yearly citations of publications by scholars accused of scientific misconduct by retraction status and time. by Giulia Maimone (20833354)

Subjects:

Estimates of the average yearly citations per publication (including all publications) by scholar group, misconduct type, and time. by Giulia Maimone (20833354)

Subjects:

(A and B) ChIP-qPCR analysis of HSF2 binding to the indicated KSHV genomic regions expressed as % of input in KSHV infected latent (A) and lytic (B) cells. by Lorenza Cutrone (21144285)

Targeted removal robustness analysis. by Fei Wang (19534)

“…TK, SOM, SUE and SALP had significant effects on the bacterial community structure of all three taxa. βNTI increased significantly with increasing differences in TN and ALSP and decreased with increasing differences in salt. …”

The network parameter at different distances. by Fei Wang (19534)

“…TK, SOM, SUE and SALP had significant effects on the bacterial community structure of all three taxa. βNTI increased significantly with increasing differences in TN and ALSP and decreased with increasing differences in salt. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”